Long-term follow-up study demonstrates durable clinical improvements and slowed brain volume loss in relapsing-remitting multiple sclerosis, suggesting sustained neuroprotection.
This study provides Class III evidence that alemtuzumab durably improves efficacy outcomes and slows BVL in patients with RRMS.
No takes yet. Share an insight, caveat, or question.
Havrdová et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: